ArticleWorld journal of gastroenterology2009
Attenuation of portal hypertension by natural taurine in rats with liver cirrhosis.
Article in World journal of gastroenterology, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 25 citations in OpenAlex.
- Emerging Therapeutic Targets for Portal Hypertension.Current hepatology reports · 2023Review
- Cellular and mitochondrial taurine depletion in bile duct ligated rats: a justification for taurine supplementation in cholestasis/cirrhosis.Clinical and experimental hepatology · 2022Article
- Diagnosis and Therapeutic Management of Liver Fibrosis by MicroRNA.International journal of molecular sciences · 2021Review
- Taurine mitigates bile duct obstruction-associated cholemic nephropathy: effect on oxidative stress and mitochondrial parameters.Clinical and experimental hepatology · 2021Article
- Taurine mitigates cirrhosis-associated heart injury through mitochondrial-dependent and antioxidative mechanisms.Clinical and experimental hepatology · 2020Article
- Natural Sulfur-Containing Compounds: An Alternative Therapeutic Strategy against Liver Fibrosis.Cells · 2019Review
- Hepatic microcirculation and mechanisms of portal hypertension.Nature reviews. Gastroenterology & hepatology · 2019Review
- Integrated network analysis of transcriptomic and protein-protein interaction data in taurine-treated hepatic stellate cells.World journal of gastroenterology · 2019Article
- Advances in therapeutic options for portal hypertension.Therapeutic advances in gastroenterology · 2018Review
- Novel treatment options for portal hypertension.Gastroenterology report · 2017Article
- Therapeutic potential of microRNA: a new target to treat intrahepatic portal hypertension?BioMed research international · 2014Review
- Natural taurine promotes apoptosis of human hepatic stellate cells in proteomics analysis.World journal of gastroenterology · 2010Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 4 institutions in 3 countries.
Funding
Abstract
aimTo investigate the inhibitory effect of natural taurine (NTau) on portal hypertension (PHT) in rats with experimentally-induced liver cirrhosis (LC).
methodsExperimentally-induced LC Wistar rats (20 rats/group) were treated with either oral saline or oral NTau for 6 consecutive weeks. Evaluation parameters included portal venous pressure (PVP), portal venous resistance (PVR), portal venous flow (PVF), splanchnic vascular resistance (SVR) and mean arterial pressure (MAP). Vasoactive substance levels including nitric oxide (NO), nitric oxide synthase (NOS) and cyclic guanosine monophosphate (cGMP) were also measured. Histological investigation of type I and III collagen (COL I and III) and transforming growth factor-beta(1) (TGF-beta1) was also performed.
resultsTreatment with NTau (1) significantly decreased PVP, PVR and PVF, and increased MAP and SVP; (2) markedly increased the vascular compliance and reduced the zero-stress of the portal vein; (3) markedly decreased the amount of NO and cGMP and activity of NOS; and (4) improved the pathological status of the liver tissue and reduced the expression of COL I, COL III and TGF-beta1.
conclusionNTau inhibited the LC-induced PHT by improving hyperdynamic circulation, morphology of liver and biomechanical properties of the portal vein in experimentally-induced LC rats.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.